SIGA Technologies, Inc. is a commercial-stage pharmaceutical company. The Company is focused on the development of medicines to treat and prevent infectious diseases. Its flagship product, TPOXX (tecovirimat), is an antiviral medicine approved in the United States and Canada for the treatment of smallpox and authorized in Europe, the United Kingdom, and Japan for the treatment of smallpox, monkeypox (mpox), cowpox, and vaccinia complications. TPOXX specifically inhibits the activity of a protein called VP37, found on the surface of all orthopoxviruses. This prevents the virus from leaving infected cells, slowing the spread of the infection and limiting it to a point where the immune system can clear the virus. The European Medicines Agency and United Kingdom approvals include labeling for oral tecovirimat indicating its use for the treatment of smallpox, monkeypox, cowpox, and vaccinia complications following vaccination against smallpox.
Growing
The company is in a growing phase, with the latest annual income totaling USD 94.57M.
High Dividend
The company is a high dividend payer, with the latest dividend payout ratio of 72.80%.
Overvalued
The company’s latest PE is 13.64, at a high 3-year percentile range.
Institutional Buying
The latest institutional holdings are 39.67M shares, increasing 0.80% quarter-over-quarter.
Held by HACAX
Star Investor HACAX holds 689.22 shares of this stock.